阿普司特对银屑病关节炎全身MRI外周及中轴炎症的影响
MOSAIC是一项4期多中心单臂开放标签研究,评估阿普司特30mg每日两次对银屑病关节炎患者全身MRI外周及中轴炎症的作用。24周和48周时,总炎症、外周炎症、外周关节炎症及脊柱炎性病灶均较基线显著下降。事后分析显示基线疾病活动中度患者MRI炎症下降更明显。
要点
- 阿普司特可显著降低银屑病关节炎患者外周和中轴MRI炎症。
- 24周和48周时总炎症、外周炎症及脊柱炎症均较基线下降。
- 基线疾病活动中度患者MRI炎症下降比高度活动者更明显。
核心结论
- 阿普司特可降低银屑病关节炎患者的外周和中轴炎症。
研究设计与样本
- MOSAIC为4期多中心单臂开放标签研究,纳入123例银屑病关节炎患者,122例接受阿普司特30mg每日两次±稳定甲氨蝶呤治疗48周。
主要发现
- 第24周和第48周总炎症最小二乘均值变化(95%CI)分别为-3.6(-6.3,-0.9)和-3.9(-7.1,-0.6)。
- 第24周和第48周总外周炎症最小二乘均值变化(95%CI)分别为-3.5(-5.5,-1.5)和-4.1(-6.4,-1.7)。
- 第24周和第48周外周关节炎症(WBSS方法)最小二乘均值变化(95%CI)分别为-3.4(-5.1,-1.7)和-3.6(-5.7,-1.5)。
- 第24周和第48周脊柱炎性病灶(Canada-Denmark方法)最小二乘均值变化(95%CI)分别为-2.6(-3.6,-1.5)和-2.1(-3.7,-0.6)。
关键数值与推荐
- 阿普司特30mg每日两次±稳定甲氨蝶呤治疗48周。
- 采用全身MRI评估外周关节、附着点、脊柱、骶髂关节、髋膝关节及足跟附着点炎症。
- 外周关节炎症采用WBSS方法评分,脊柱炎症采用Canada-Denmark方法评分。
临床怎么用
- 阿普司特治疗可改善银屑病关节炎患者外周及中轴MRI炎症,支持其用于控制影像学炎症。
局限性
- 本研究为单臂开放标签设计,无对照组。
- 部分分析为事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the effect of apremilast on peripheral and axial psoriatic arthritis (PsA) manifestations as assessed by whole-body magnetic resonance imaging (WB-MRI), including the effect of apremilast on inflammation in all peripheral joints and entheses, spine and sacroiliac joints, hip and knee joints, and heel entheses. METHODS: MOSAIC was a phase 4, multicentre, single-arm, open-label study of apremilast 30 mg twice daily ± concomitant stable methotrexate for 48 weeks in patients with PsA (NCT03783026). MRI of the clinically most affected hand and whole body was performed at baseline, 24 weeks, and 48 weeks. Here, we report secondary and post hoc outcomes of changes from baseline to weeks 24 and 48 in axial or peripheral inflammation, based on WB-MRI assessment. RESULTS: Overall, 123 patients were enrolled across 29 global locations and 122 were treated with apremilast and included in this analysis. At weeks 24 and 48, respectively, statistically significant decreases were observed from baseline in least squares mean (95% CI) for total (peripheral + axial) inflammation (-3.6 [-6.3, -0.9] and -3.9 [-7.1, -0.6]), total peripheral inflammation (-3.5 [-5.5, -1.5] and -4.1 [-6.4, -1.7]), peripheral joint inflammation (by Whole-Body Scoring System for Inflammation in Peripheral Joints and Entheses in Inflammatory Arthritis method; -3.4 [-5.1, -1.7] and -3.6 [-5.7, -1.5]), and inflammatory lesions of the spine (by Canada-Denmark method; -2.6 [-3.6, -1.5] and -2.1 [-3.7, -0.6]). Post hoc analyses showed that decreases in MRI inflammation were more prominent in patients with moderate vs high baseline disease activity. CONCLUSIONS: Apremilast reduced both peripheral and axial inflammation in patients with PsA.
引用
- Østergaard M, Lambert RGW, Maksymowych WP, et al. Effect of apremilast on whole-body magnetic resonance imaging of peripheral and axial inflammation in patients with psoriatic arthritis. Ann Rheum Dis. 2026. PMID: 42191498. doi:10.1016/j.ard.2026.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。